Noticias y Actividades de Madrigal Pharmaceuticals
Presencia
Madrigal Pharmaceuticals es una de las ...
Madrigal Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización MDGL (US).
Ejecutivos
Ver el organigrama con sus 31 ejecutivos principales
Biografías más buscadas en Madrigal Pharmaceuticals
- Bill Sibold, Chief Executive Officer and Director
- Paul Friedman, Director
- Fred Craves, Lead Director
Recientes movimientos de ejecutivos en Madrigal Pharmaceuticals
- David Soergel, se ha incorporado a la empresa como Chief Medical Officer (noticia publicada el 16 de abril de 2025).
- Jacqualyn Fouse, se ha incorporado a la empresa como Director (noticia publicada el 13 de marzo de 2025).
- Michael Charlton, se ha incorporado a la empresa como Senior Vice President, Clinical Development (noticia publicada el 2 de octubre de 2024).
Haga clic aquí para ver otros movimientos en Madrigal Pharmaceuticals
Crear su alerta
para seguir los movimientos de los ejecutivos en Madrigal Pharmaceuticals.
Farmacia
Madrigal Pharmaceuticals tiene 1.830 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).
Popular M&A news in Farmacia
- Chimerix and Chimerix have merged (publicado el 22 de abril de 2025)..
- Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
- Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Madrigal Pharmaceuticals
- Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences | Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates | Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® | Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis | Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 | Madrigal Pharmaceuticals.
- Press Releases | Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference | Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development | Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom) | Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference | Madrigal Pharmaceuticals.
- View more press releases Close
Redes sociales sobre Madrigal Pharmaceuticals
- Madrigal Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Madrigal Pharmaceuticals en LinkedIn, Twitter y YouTube
